Healthcare: Will Shire Be Bought Out? Plus, Alkermes Suffers a Setback

Industry Focus - Podcast készítő The Motley Fool

Takeda may buy Shire, but it might prove costly. Also, the FDA slaps Alkermes with a dreaded Refusal to File letter.